First Vyluma product tackles pediatric myopia

Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.

Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.

Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.

Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.

David Webley, BSc (Hons), MCOptom, FBCLA, weighs in on SightGlass Vision's latest data presented at AAOpt's annual meeting in Anaheim, California.

Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.

A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no serious adverse events reported.

Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.